Steven S. Williamson is recorded as Board Member and CEO at Pulmonx Corp (LUNG) since March 15, 2024. Pulmonx Corp reported in an 8-K filed October 27, 2025 that Steven S. Williamson resigned as member of the Board of Directors, effective October 27, 2025. Pulmonx Corp reported in an 8-K filed October 27, 2025 that Steven S. Williamson resigned as President and Chief Executive Officer, effective October 27, 2025. Pulmonx Corp reported in an 8-K filed February 21, 2024 that Steven S. Williamson was appointed Class II member of the board of directors, effective March 15, 2024. Equibles holds 4 filed executive changes naming Steven S. Williamson; each is listed under recent activity with its source filing. The proxy statement of Pulmonx Corp reports total compensation of $5,234,479 for Steven S. Williamson in fiscal 2024, including a base salary of $461,398. Disclosed compensation is on record for 2 fiscal years. Steven S. Williamson has spoken on 1 earnings call across 1 company, most recently for Pulmonx Corp on October 30, 2024. Pulmonx Corp is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Pulmonx Corp includes Glendon E. French (CEO and Board Member), Glendon French (CEO and Board Member), Derrick Sung (CFO and COO) and 4 others.
“On October 21, 2025, Steven S. Williamson resigned as President and Chief Executive Officer and a member of the Board of Directors of Pulmonx Corporation (the "Company"), effective as of October 27, 2025 (the "Effective Date").”
Pulmonx Corp Form 8-K, filed October 27, 2025
· Read the filing
“On October 21, 2025, Steven S. Williamson resigned as President and Chief Executive Officer and a member of the Board of Directors of Pulmonx Corporation (the "Company"), effective as of October 27, 2025 (the "Effective Date").”
Pulmonx Corp Form 8-K, filed October 27, 2025
· Read the filing
Steven S. Williamson on recent calls
“Here with me is Mehul Joshi, our Chief Financial Officer. I am pleased with our third quarter performance and our team’s continued execution across several of our most critical commercial and clinical initiatives.”
